| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 All authors: Sardinian Mediterranean Imaging Research Group, Via Gorizia no. 11, Sassari 07100, Sardinia, Italy.
OBJECTIVE. The aim of this study was to characterize focal hepatic lesions using agent detection imaging and Levovist.
MATERIALS AND METHODS. Sixty-five patients (21 male and 44 female; age range, 8–82 years; mean ± standard deviation, 58.1 ± 14.5 years) were independently evaluated by two observers in a blinded manner using stored sonographic images. Seventy-five lesions were found: 15 hepatocellular carcinomas, nine focal nodular hyperplasias, two adenomas, 21 hemangiomas, 23 metastases, and five regenerative nodules. Nine patients were excluded (six because of technical failures, three with unproven diagnoses). New high-mechanical-index software was used to reveal power harmonic responses from contrast microbubble destruction. After a venous bolus injection of 4 g of Levovist at a strength of 400 mg/mL, delayed imaging was used to study lesion enhancement in the arterial, portal, and parenchymal phases. Two comparisons were made. The first was between the B-mode image and the first contrast-enhanced image after the flash. The second was between color Doppler sonograms and real-time contrast-enhanced perfusion images.
RESULTS. Contrast-enhanced images after the flash and real-time contrast-enhanced images revealed more information for the characterization of the lesion than did gray-scale and color Doppler images (p < 0.0001, Wilcoxon's signed rank test). Different types of lesions showed statistically significant differences in enhancement during each of the three vascular phases (p < 0.005, Kruskal-Wallis test). Lesions with lower contrast enhancement were metastases and regenerating nodules. Good agreement was present between the two observers; differences were not statistically significant (p > 0.05).
CONCLUSION. Agent detection imaging with Levovist increased diagnostic confidence in the characterization of focal hepatic lesions as compared with standard sonography.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Ricci, V. Cantisani, M. D'Onofrio, D. Sahani, E. Pagliara, F. Calliada, E. Mehmet, K. Sanjeva, N. Faccioli, R. Pozzi-Mucelli, et al. Behavior of Hepatocellular Adenoma on Real-time Low-Mechanical Index Contrast-Enhanced Ultrasonography With a Second-Generation Contrast Agent J. Ultrasound Med., December 1, 2008; 27(12): 1719 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Catalano, V. Migaleddu, E. Quaia, and G. Caruso Terminology for Contrast-Enhanced Sonography: A Practical Glossary J. Ultrasound Med., June 1, 2007; 26(6): 717 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Catalano, F. Sandomenico, A. Nunziata, M. M. Raso, P. Vallone, and A. Siani Transient Hepatic Echogenicity Difference on Contrast-Enhanced Ultrasonography: Sonographic Sign and Pitfall J. Ultrasound Med., March 1, 2007; 26(3): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Minami, M. Kudo, H. Chung, T. Kawasaki, Y. Yagyu, T. Shimono, and H. Shiozaki Contrast Harmonic Sonography-Guided Radiofrequency Ablation Therapy Versus B-Mode Sonography in Hepatocellular Carcinoma: Prospective Randomized Controlled Trial Am. J. Roentgenol., February 1, 2007; 188(2): 489 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Leen, P. Ceccotti, C. Kalogeropoulou, W. J. Angerson, S. J. Moug, and P. G. Horgan Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. Am. J. Roentgenol., June 1, 2006; 186(6): 1551 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Catalano, A. Nunziata, R. Lobianco, and A. Siani Real-Time Harmonic Contrast Material-specific US of Focal Liver Lesions RadioGraphics, March 1, 2005; 25(2): 333 - 349. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
